Danaher Co. (NYSE:DHR) Shares Sold by AustralianSuper Pty Ltd

AustralianSuper Pty Ltd lessened its holdings in Danaher Co. (NYSE:DHR) by 25.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 552,438 shares of the conglomerate’s stock after selling 188,318 shares during the quarter. AustralianSuper Pty Ltd owned about 0.08% of Danaher worth $138,027,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in Danaher by 7.4% during the first quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock valued at $15,009,928,000 after purchasing an additional 4,163,657 shares during the period. Wellington Management Group LLP boosted its stake in shares of Danaher by 12.0% in the fourth quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock worth $6,460,966,000 after buying an additional 2,998,161 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Danaher by 10.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock worth $3,876,694,000 after acquiring an additional 1,619,586 shares during the period. Capital International Investors raised its position in Danaher by 9.1% during the fourth quarter. Capital International Investors now owns 15,956,519 shares of the conglomerate’s stock valued at $3,691,735,000 after acquiring an additional 1,334,781 shares in the last quarter. Finally, Norges Bank acquired a new position in Danaher in the fourth quarter valued at approximately $1,752,382,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

DHR has been the subject of several recent research reports. Bank of America lifted their target price on shares of Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Jefferies Financial Group began coverage on shares of Danaher in a research report on Monday, June 3rd. They issued a “buy” rating and a $295.00 price objective for the company. Evercore ISI dropped their target price on Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 2nd. Leerink Partners upped their price target on Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Finally, Robert W. Baird increased their price target on Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $278.94.

Danaher Trading Up 0.3 %

NYSE:DHR traded up $0.75 during trading hours on Tuesday, hitting $268.82. The company had a trading volume of 1,552,474 shares, compared to its average volume of 2,804,287. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. The company has a market cap of $199.11 billion, a P/E ratio of 45.56, a P/E/G ratio of 4.62 and a beta of 0.83. The company has a 50-day moving average of $259.00 and a 200 day moving average of $254.60. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $281.70.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter in the prior year, the company posted $2.05 earnings per share. Danaher’s revenue for the quarter was down 2.9% compared to the same quarter last year. Sell-side analysts expect that Danaher Co. will post 7.59 earnings per share for the current year.

Insider Buying and Selling at Danaher

In other Danaher news, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the sale, the chief executive officer now directly owns 97,983 shares in the company, valued at $27,435,240. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the sale, the chief executive officer now owns 97,983 shares in the company, valued at approximately $27,435,240. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Matthew Mcgrew sold 16,172 shares of the stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the completion of the transaction, the chief financial officer now directly owns 29,407 shares in the company, valued at $8,229,254.88. The disclosure for this sale can be found here. Insiders sold a total of 39,659 shares of company stock valued at $11,042,433 in the last three months. 11.10% of the stock is owned by corporate insiders.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.